ARVN Q3 2023 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$35M+4.2% YoY

Gross Profit

$33M95.1% margin

Operating Income

-$74M-213.6% margin

Net Income

-$64M-185.0% margin

EPS (Diluted)

$-1.18

QoQ Revenue Growth

-36.5%

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$86M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$601M

Stockholders' Equity

$457M

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$33M	+4.2%
Gross Profit	$33M	$31M	+5.8%
Operating Income	-$74M	-$64M	-14.9%
Net Income	-$64M	-$66M	+3.3%